{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:46:20Z","timestamp":1792089980578,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00520-026-11136-5","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:55:26Z","timestamp":1788400526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timing of bone-modifying agent initiation and skeletal-related event risk in patients with bone metastases from solid tumors: a retrospective landmark and propensity score\u2013matched analysis"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5205-7258","authenticated-orcid":false,"given":"Tatsuki","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3179-677X","authenticated-orcid":false,"given":"Satoru","family":"Nihei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1117-7648","authenticated-orcid":false,"given":"Kazuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2478-0190","authenticated-orcid":false,"given":"Junya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9902-3449","authenticated-orcid":false,"given":"Kenzo","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"9","key":"11136_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239482","volume":"15","author":"S Hong","year":"2020","unstructured":"Hong S, Youk T, Lee SJ, Kim KM, Vajdic CM (2020) Bone metastasis and skeletal-related events in patients with solid cancer: a Korean nationwide health insurance database study. PLoS ONE 15(9):e0239482. https:\/\/doi.org\/10.1371\/journal.pone.0239482","journal-title":"PLoS ONE"},{"issue":"Suppl 4","key":"11136_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1634\/theoncologist.9-suppl_4-14","volume":"9","author":"RE Coleman","year":"2004","unstructured":"Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(Suppl 4):14\u201327. https:\/\/doi.org\/10.1634\/theoncologist.9-suppl_4-14","journal-title":"Oncologist"},{"issue":"20","key":"11136_CR3","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE, Brown JE, Cook RJ, Lipton A, Hirsh V, Scardino PT et al (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20):6243s\u20136249s. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0931","journal-title":"Clin Cancer Res"},{"key":"11136_CR4","doi-asserted-by":"publisher","first-page":"742","DOI":"10.5035\/nishiseisai.52.742","volume":"52","author":"H Yamashita","year":"2003","unstructured":"Yamashita H, Osaki M, Endo K, Minamizaki T, Teshima R (2003) Frequency of bone metastasis in cancer: a retrospective analysis of 365 autopsy cases. Orthop Traumatol 52:742\u2013745","journal-title":"Orthop Traumatol"},{"issue":"4","key":"11136_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1634\/theoncologist.2015-0341","volume":"21","author":"R Tanaka","year":"2016","unstructured":"Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Takahashi N, Hashimoto J et al (2016) Risk factors for developing skeletal-related events in breast cancer patients with bone metastases undergoing treatment with bone-modifying agents. Oncologist 21(4):508\u2013513. https:\/\/doi.org\/10.1634\/theoncologist.2015-0341","journal-title":"Oncologist"},{"issue":"35","key":"11136_CR6","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132\u20135139. https:\/\/doi.org\/10.1200\/JCO.2010.29.7101","journal-title":"J Clin Oncol"},{"issue":"9768","key":"11136_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(10)62344-6","journal-title":"Lancet"},{"issue":"9","key":"11136_CR8","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29(9):1125\u20131132. https:\/\/doi.org\/10.1200\/JCO.2010.31.3304","journal-title":"J Clin Oncol"},{"issue":"16","key":"11136_CR9","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.01.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082\u20133092. https:\/\/doi.org\/10.1016\/j.ejca.2012.01.002","journal-title":"Eur J Cancer"},{"issue":"3","key":"11136_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00520-013-2021-8","volume":"22","author":"D Henry","year":"2014","unstructured":"Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L et al (2014) Delaying skeletal- related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer 22(3):679\u2013687. https:\/\/doi.org\/10.1007\/s00520-013-2021-8","journal-title":"Support Care Cancer"},{"issue":"1","key":"11136_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1470-2045(13)70504-6","volume":"15","author":"P Barrett-Lee","year":"2014","unstructured":"Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P et al (2014) Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol 15(1):114\u2013122. https:\/\/doi.org\/10.1016\/S1470-2045(13)70504-6","journal-title":"Lancet Oncol"},{"issue":"5","key":"11136_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069214","volume":"13","author":"A Seesaghur","year":"2023","unstructured":"Seesaghur A, Egger P, Warden J, Abbasi A, Levick B, Riaz M et al (2023) Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital. BMJ Open 13(5):e069214. https:\/\/doi.org\/10.1136\/bmjopen-2022-069214","journal-title":"BMJ Open"},{"issue":"9","key":"11136_CR13","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","volume":"29","author":"CH Van Poznak","year":"2011","unstructured":"Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, Von Roenn JH, American Society of Clinical Oncology (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29(9):1221\u20131227. https:\/\/doi.org\/10.1200\/JCO.2010.32.5209","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"11136_CR14","doi-asserted-by":"publisher","first-page":"vi25","DOI":"10.1093\/annonc\/mdr372","volume":"22","author":"F Cardoso","year":"2011","unstructured":"Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E, ESMO Guidelines Working Group (2011) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi25-30. https:\/\/doi.org\/10.1093\/annonc\/mdr372","journal-title":"Ann Oncol"},{"issue":"1","key":"11136_CR15","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s13277-015-3870-3","volume":"37","author":"A Ulas","year":"2016","unstructured":"Ulas A, Bilici A, Durnali A, Tokluoglu S, Akinci S, Silay K et al (2016) Risk factors for skeletal- related events and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases. Tumour Biol 37(1):1131\u20131140. https:\/\/doi.org\/10.1007\/s13277-015-3870-3","journal-title":"Tumour Biol"},{"key":"11136_CR16","doi-asserted-by":"publisher","unstructured":"Sato J, Ikeda T, Nihei S, Tanaka R, Murotani K, Kudo K, Kanehira D, Azuma T, Shibata H (2025) Timing of bone-modifying agents after bone metastasis diagnosis and time to first skeletal-related event: a systematic review and study-level correlation analysis. J Oncol Pharm Pract. https:\/\/doi.org\/10.1177\/10781552251399902","DOI":"10.1177\/10781552251399902"},{"issue":"12","key":"11136_CR17","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, Oudard S, Bruland \u00d8, Flamen P, Kurth A, Van Poznak C, Aapro M, Jordan K, ESMO Guidelines Committee (2020) Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 31(12):1650\u20131663. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.019","journal-title":"Ann Oncol"},{"issue":"7","key":"11136_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.21.02647","volume":"40","author":"A Eisen","year":"2022","unstructured":"Eisen A, Somerfield MR, Accordino MK, Blanchette PS, Clemons MJ, Dhesy-Thind S, Dillmon MS, D\u2019Oronzo S, Fletcher GG, Frank ES, Hallmeyer S, Makhoul I, Moy B, Thawer A, Wu JY, Van Poznak CH (2022) Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. J Clin Oncol 40(7):787\u2013800. https:\/\/doi.org\/10.1200\/JCO.21.02647","journal-title":"J Clin Oncol"},{"issue":"5","key":"11136_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxillofac Surg 80(5):920\u2013943. https:\/\/doi.org\/10.1016\/j.joms.2022.02.008","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"11136_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O\u2019Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, S\u00e1ndor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, International Task Force on Osteonecrosis of the Jaw (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30(1):3\u201323. https:\/\/doi.org\/10.1002\/jbmr.2405","journal-title":"J Bone Miner Res"},{"issue":"5","key":"11136_CR21","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s10147-013-0643-5","volume":"19","author":"H Yamashiro","year":"2014","unstructured":"Yamashiro H, Takada M, Nakatani E, Imai S, Yamauchi A, Tsuyuki S, Matsutani Y, Sakata S, Wada Y, Okamura R, Harada T, Tanaka F, Moriguchi Y, Kato H, Higashide S, Kan N, Yoshibayashi H, Suwa H, Okino T, Nakayama I, Ichinose Y, Yamagami K, Hashimoto T, Inamoto T, Toi M (2014) Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan. Int J Clin Oncol 19(5):852\u2013862. https:\/\/doi.org\/10.1007\/s10147-013-0643-5","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"11136_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10549-020-05712-4","volume":"182","author":"H Miyashita","year":"2020","unstructured":"Miyashita H, Cruz C, Malamud S (2020) Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate. Breast Cancer Res Treat 182(2):381\u2013388. https:\/\/doi.org\/10.1007\/s10549-020-05712-4","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"11136_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0328792","volume":"20","author":"M Hamada","year":"2025","unstructured":"Hamada M, Nakata E, Nakahara R, Sugihara S, Katayama H, Itano T, Inoue T, Takihira S, Akezaki Y, Ozaki T (2025) Risk stratification for the prediction of skeletal-related events in patients with castration-resistant prostate cancer with bone metastases. PLoS ONE 20(8):e0328792. https:\/\/doi.org\/10.1371\/journal.pone.0328792","journal-title":"PLoS ONE"},{"issue":"10","key":"11136_CR24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.95808","volume":"17","author":"Y Sakamoto","year":"2025","unstructured":"Sakamoto Y, Nakata E, Hamada M, Katayama Y, Sugihara S, Ozaki T (2025) Risk stratification for the prediction of skeletal-related events in patients with bone metastases from non-small cell lung cancer. Cureus 17(10):e95808. https:\/\/doi.org\/10.7759\/cureus.95808","journal-title":"Cureus"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11136-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11136-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11136-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:48:29Z","timestamp":1792086509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11136-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11136"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11136-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8635323\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in compliance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects issued by the Ministry of Health, Labour, and Welfare of Japan and the Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee of Iwate Medical University (MH2024-155). Due to the retrospective nature of the study, which involved the analysis of existing clinical data, the requirement for individual informed consent was waived by the ethics committee. All patient data were anonymized and de-identified before analysis to ensure confidentiality.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"925"}}